Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Role of endothelin in systemic and portal resistance in cirrhosis.

Literature DB >> 16905694

Role of endothelin in systemic and portal resistance in cirrhosis.

P W Angus¹.

Abstract

Entities: Disease

Mesh：

Substances：

Year: 2006 PMID： 16905694 PMCID： PMC1860042 DOI： 10.1136/gut.2005.088633

Source DB: PubMed Journal: Gut ISSN： 0017-5749 Impact factor: 23.059

× No keyword cloud information.

36 in total

1. Amelioration of hepatorenal syndrome with selective endothelin-A antagonist.

Authors: C P Soper; A B Latif; M R Bending
Journal: Lancet Date: 1996-06-29 Impact factor: 79.321

2. Cellular localization of endothelin-1 and increased production in liver injury in the rat: potential for autocrine and paracrine effects on stellate cells.

Authors: D C Rockey; L Fouassier; J J Chung; A Carayon; P Vallee; C Rey; C Housset
Journal: Hepatology Date: 1998-02 Impact factor: 17.425

3. Endothelin-1 induces liver vasoconstriction through both ETA and ETB receptors.

Authors: B Zhang; Y Calmus; L Wen; P Sogni; S Lotersztajn; D Houssin; B Weill
Journal: J Hepatol Date: 1997-05 Impact factor: 25.083

4. Endothelin induced contractility of stellate cells from normal and cirrhotic rat liver: implications for regulation of portal pressure and resistance.

Authors: D C Rockey; R A Weisiger
Journal: Hepatology Date: 1996-07 Impact factor: 17.425

Review 5. Pulmonary hypertension in chronic liver disease.

Authors: M S Mandell; B M Groves
Journal: Clin Chest Med Date: 1996-03 Impact factor: 2.878

6. Endothelin 1 is overexpressed in human cirrhotic liver and exerts multiple effects on activated hepatic stellate cells.

Authors: M Pinzani; S Milani; R De Franco; C Grappone; A Caligiuri; A Gentilini; C Tosti-Guerra; M Maggi; P Failli; C Ruocco; P Gentilini
Journal: Gastroenterology Date: 1996-02 Impact factor: 22.682

7. Plasma endothelin immunoreactivity in liver disease and the hepatorenal syndrome.

Authors: K Moore; J Wendon; M Frazer; J Karani; R Williams; K Badr
Journal: N Engl J Med Date: 1992-12-17 Impact factor: 91.245

8. The effect of endothelin and its antagonist Bosentan on hemodynamics and microvascular exchange in cirrhotic rat liver.

Authors: J Reichen; A L Gerbes; M J Steiner; H Sägesser; M Clozel
Journal: J Hepatol Date: 1998-06 Impact factor: 25.083

Role of endothelin in systemic and portal resistance in cirrhosis.

1. Amelioration of hepatorenal syndrome with selective endothelin-A antagonist.

2. Cellular localization of endothelin-1 and increased production in liver injury in the rat: potential for autocrine and paracrine effects on stellate cells.

3. Endothelin-1 induces liver vasoconstriction through both ETA and ETB receptors.

4. Endothelin induced contractility of stellate cells from normal and cirrhotic rat liver: implications for regulation of portal pressure and resistance.

Review 5. Pulmonary hypertension in chronic liver disease.

6. Endothelin 1 is overexpressed in human cirrhotic liver and exerts multiple effects on activated hepatic stellate cells.

7. Plasma endothelin immunoreactivity in liver disease and the hepatorenal syndrome.

8. The effect of endothelin and its antagonist Bosentan on hemodynamics and microvascular exchange in cirrhotic rat liver.

9. Endothelin ETA and ETB receptors cause vasoconstriction of human resistance and capacitance vessels in vivo.

10. Endothelin-1 and endothelin-3 in cirrhosis: relations to systemic and splanchnic haemodynamics.

1. Increased endothelin receptor B and G protein coupled kinase-2 in the mesentery of portal hypertensive rats.

2. Therapeutic potential of targeting the renin angiotensin system in portal hypertension.

Review 3. Ascites and spontaneous bacterial peritonitis: recommendations from two United States centers.

Review 4. Role of the renin-angiotensin system in hepatic fibrosis and portal hypertension.

5. Endothelin receptors promote schistosomiasis-induced hepatic fibrosis via splenic B cells.

6. Phosphodiesterase-5 inhibitors have distinct effects on the hemodynamics of the liver.

Review 7. Cirrhotic portal hypertension: From pathophysiology to novel therapeutics.